Compare · LEXX vs NVO
LEXX vs NVO
Side-by-side comparison of Lexaria Bioscience Corp. (LEXX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEXX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.46B, about 28053.2x LEXX ($6.8M).
- LEXX has been more active in the news (8 items in the past 4 weeks vs 7 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for LEXX).
- Company
- Lexaria Bioscience Corp.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $6.8M
- $191.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 7
- Recent ratings
- 0
- 25
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LEXX
- Lexaria Updates Financial Position
- Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
- Lexaria Bioscience Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
- Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Lexaria Bioscience Corp. filed SEC Form 8-K: Other Events
- Lexaria Receives USD$2.6 Million Tax Rebate Payment
- DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
- Lexaria Bioscience Corp. filed SEC Form 8-K: Other Events
- Lexaria Enters a Material Transfer Agreement With PegBio
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg